TY - JOUR
T1 - Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury
AU - Yune, Tae Y.
AU - Lee, Jee Y.
AU - Jung, Gil Y.
AU - Kim, Sun J.
AU - Jiang, Mei H.
AU - Kim, Young C.
AU - Oh, Young J.
AU - Markelonis, George J.
AU - Oh, Tae H.
PY - 2007/7/18
Y1 - 2007/7/18
N2 - Spinal cord injury (SCI) causes a permanent neurological disability, and no satisfactory treatment is currently available. After SCI, pro-nerve growth factor (proNGF) is known to play a pivotal role in apoptosis of oligodendrocytes, but the cell types producing proNGF and the signaling pathways involved in proNGF production are primarily unknown. Here, we show that minocycline improves functional recovery after SCI in part by reducing apoptosis of oligodendrocytes via inhibition of proNGF production in microglia. After SCI, the stress-responsive p38 mitogen-activated protein kinase (p38MAPK) was activated only in microglia, and proNGF was produced by microglia via the p38MAPK-mediated pathway. Minocycline treatment significantly reduced proNGF production in microglia in vitro and in vivo by inhibition of the phosphorylation of p38MAPK. Furthermore, minocycline treatment inhibited p75 neurotrophin receptor expression and RhoA activation after injury. Finally, minocycline treatment inhibited oligodendrocyte death and improved functional recovery after SCI. These results suggest that minocycline may represent a potential therapeutic agent for acute SCI in humans.
AB - Spinal cord injury (SCI) causes a permanent neurological disability, and no satisfactory treatment is currently available. After SCI, pro-nerve growth factor (proNGF) is known to play a pivotal role in apoptosis of oligodendrocytes, but the cell types producing proNGF and the signaling pathways involved in proNGF production are primarily unknown. Here, we show that minocycline improves functional recovery after SCI in part by reducing apoptosis of oligodendrocytes via inhibition of proNGF production in microglia. After SCI, the stress-responsive p38 mitogen-activated protein kinase (p38MAPK) was activated only in microglia, and proNGF was produced by microglia via the p38MAPK-mediated pathway. Minocycline treatment significantly reduced proNGF production in microglia in vitro and in vivo by inhibition of the phosphorylation of p38MAPK. Furthermore, minocycline treatment inhibited p75 neurotrophin receptor expression and RhoA activation after injury. Finally, minocycline treatment inhibited oligodendrocyte death and improved functional recovery after SCI. These results suggest that minocycline may represent a potential therapeutic agent for acute SCI in humans.
UR - http://www.scopus.com/inward/record.url?scp=34447643571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447643571&partnerID=8YFLogxK
U2 - 10.1523/JNEUROSCI.1661-07.2007
DO - 10.1523/JNEUROSCI.1661-07.2007
M3 - Article
C2 - 17634369
AN - SCOPUS:34447643571
SN - 0270-6474
VL - 27
SP - 7751
EP - 7761
JO - Journal of Neuroscience
JF - Journal of Neuroscience
IS - 29
ER -